InfuSystem projects 2024 revenue of $134.2M and adjusted EBITDA of $26.5M

InfuSystem Holdings, Inc

2023 revenue $125.8M (12% CAGR over 5 years); adjusted EBITDA $22.4M.
Q1 2024 revenue $32.0M; adjusted EBITDA $3.9M (vs. $4.2M in Q1 2023).
Guidance: 2024 revenue ~$134.2M (high single-digit growth); adjusted EBITDA ~$26.5M (margin 19.7%).
Patient Services gross margin stable at ~63%; Device Solutions gross margin declined to 31.5% (TTM).
Capital allocation: $20M share repurchase program; net leverage 1.32x; NOLs $26.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.